Founding Director Robert T. Nelsen to Retire from Adolor Board

  
    
  
  
    
      Adolor Corporation (Nasdaq:ADLR) announced today that Robert T. Nelsen 
      is retiring from his role as a member of the Board of Directors of 
      Adolor Corporation effective May 21, 2008. Mr. Nelsen is a founder of 
      Adolor and has served on the Board of Directors since its inception.
    
    
      “We thank Bob for his outstanding dedication, 
      service and contribution to Adolor,” said 
      David M. Madden, chairman of the Adolor Board of Directors. “Bob 
      has been instrumental over the past 15 years in helping to take Adolor 
      from an idea to one of the few emerging pharmaceutical companies to have 
      made the transition from research to commercialization.”
    
    
      “With the recent FDA approval of Entereg® 
      in postoperative ileus, Bob’s vision that 
      novel science in the area of opioid receptors would someday improve 
      patient care is now a reality,” said Michael 
      R. Dougherty, Adolor chief executive officer. “We 
      are grateful to Bob for sharing his wisdom, experience and leadership 
      with us for all these years, and wish him continued success in his 
      future business endeavors.”
    
    
      About Adolor Corporation
    
    
      Adolor Corporation (Nasdaq:ADLR) is a biopharmaceutical company 
      specializing in the discovery, development and commercialization of 
      novel prescription pain management products. By applying its knowledge 
      and expertise in pain management, along with ingenuity, Adolor is 
      seeking to make a positive difference for patients, caregivers and the 
      medical community. For more information, visit www.adolor.com.
    
    
      This release, and oral statements made with respect to information 
      contained in this release, may constitute forward-looking statements 
      within the meaning of the Private Securities Litigation Reform Act of 
      1995. Such forward-looking statements include those which express 
      plan, anticipation, intent, contingency, goals, targets or future 
      development and/or otherwise are not statements of historical fact. These 
      statements are based upon management's current expectations and are 
      subject to risks and uncertainties, known and unknown, which could cause 
      actual results and developments to differ materially from those 
      expressed or implied in such statements. Information about risks 
      and uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and 
      10-K filed with the U.S. Securities and Exchange Commission. Adolor 
      urges you to carefully review and consider the disclosures found in its 
      filings which are available in the SEC EDGAR database at http://www.sec.gov 
      and from Adolor at http://www.adolor.com.
    
    
      Given the uncertainties affecting pharmaceutical companies in the 
      development stage, you are cautioned not to place undue reliance on any 
      such forward-looking statements, any of which may turn out to be wrong 
      due to inaccurate assumptions, unknown risks, uncertainties or other 
      factors. Adolor undertakes no obligation to (and expressly 
      disclaims any such obligation to) publicly update or revise the 
      statements made herein or the risk factors that may relate thereto 
      whether as a result of new information, future events, or otherwise.
    
    
      This press release is available on the website http://www.adolor.com.